Fig. 2

Effect of HQS and OS on mice infected with influenza. A (lung index, n ≥ 8) and B (lung pathology, × 100, n = 7) represent the results of experiment 1 “Therapeutic effect of HQS on influenza pneumonia in mice.” Mice were intranasally infected with 15 LD₅₀ of influenza virus. Six groups of mice were simultaneously treated orally with HQS low-, middle-, and high-dose (330, 165, and 82.5 mg/kg/d), Oseltamivir (OS, 27.5 mg/kg/d), or distilled water (control and model group) for 5 days. On day 5 post infection, the lungs of the mice were collected for further analysis. C (lung index, n = 10) and D (lung pathology, × 100, n = 7) represent the results of experiment 2 “Preventive effect of HQS on influenza pneumonia in mice.” Mice were treated with HQS low-, middle-, and high-dose (330, 165, and 82.5 mg/kg/d), Oseltamivir (OS, 27.5 mg/kg/d), or distilled water (control and model group) once daily for 3 days through gavage. After the last administration, the mice were intranasally infected with 15 LD₅₀ of influenza A virus. On day 4 after infection, the lungs of the mice were collected for further analysis. Results are expressed as mean ± SD, ^*P < 0.05, ^**P < 0.01, compared to the model group